Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05840211 |
|---|---|
| Brief Title: | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) |
| First Submitted : | April 21, 2023 |
| First Submitted that Met QC Criteria : | April 21, 2023 |
| First Posted : | May 3, 2023 |
| Last Update Submitted that Met QC Criteria : | February 26, 2024 |
| Last Update Posted : | February 28, 2024 |